126 related articles for article (PubMed ID: 16247958)
1. Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECyd).
Hrdlicka PJ; Jepsen JS; Wengel J
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):397-400. PubMed ID: 16247958
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
Hrdlicka PJ; Jepsen JS; Nielsen C; Wengel J
Bioorg Med Chem; 2005 Feb; 13(4):1249-60. PubMed ID: 15670934
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of branched and conformationally restricted analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
Hrdlicka PJ; Andersen NK; Jepsen JS; Hansen FG; Haselmann KF; Nielsen C; Wengel J
Bioorg Med Chem; 2005 Apr; 13(7):2597-621. PubMed ID: 15755661
[TBL] [Abstract][Full Text] [Related]
4. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic mechanisms of new antitumor nucleoside analogues, 3'-ethynylcytidine (ECyd) and 3'-ethynyluridine (EUrd).
Kanda H; Takatori S; Matsuda A; Sasaki T; Tanaka M; Fukushima M; Wataya Y
Nucleic Acids Symp Ser; 1997; (37):137-8. PubMed ID: 9586037
[TBL] [Abstract][Full Text] [Related]
6. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil.
Takatori S; Kanda H; Takenaka K; Wataya Y; Matsuda A; Fukushima M; Shimamoto Y; Tanaka M; Sasaki T
Cancer Chemother Pharmacol; 1999; 44(2):97-104. PubMed ID: 10412942
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers].
Tanaka M; Tabata S; Matsuda A; Fukushima M; Eshima K; Sasaki T
Gan To Kagaku Ryoho; 1997 Feb; 24(4):476-82. PubMed ID: 9063487
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor mechanisms of 3'-ethynyluridine and 3'-ethynylcytidine as RNA synthesis inhibitors: development and characterization of 3'-ethynyluridine-resistant cells.
Tabata S; Tanaka M; Endo Y; Obata T; Matsuda A; Sasaki T
Cancer Lett; 1997 Jun; 116(2):225-31. PubMed ID: 9215867
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Schott H; Schott S; Schwendener RA
Bioorg Med Chem; 2009 Oct; 17(19):6824-31. PubMed ID: 19744858
[TBL] [Abstract][Full Text] [Related]
10. A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides.
Murata D; Endo Y; Obata T; Sakamoto K; Syouji Y; Kadohira M; Matsuda A; Sasaki T
Drug Metab Dispos; 2004 Oct; 32(10):1178-82. PubMed ID: 15280220
[TBL] [Abstract][Full Text] [Related]
11. Anticancer molecular mechanism of 3'-ethynylcytidine (ECyd).
Wataya Y; Futagami M; Naito T; Uchikubo Y; Yokogawa T; Takenaka K; Kim HS; Matsuda A; Fukushima M; Kitade Y
Nucleic Acids Res Suppl; 2001; (1):233-4. PubMed ID: 12836350
[TBL] [Abstract][Full Text] [Related]
12. ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2011 Jun; 29(3):506-13. PubMed ID: 19997962
[TBL] [Abstract][Full Text] [Related]
13. Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and -uracil1.
Hattori H; Nozawa E; Iino T; Yoshimura Y; Shuto S; Shimamoto Y; Nomura M; Fukushima M; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1998 Jul; 41(15):2892-902. PubMed ID: 9667977
[TBL] [Abstract][Full Text] [Related]
14. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
[TBL] [Abstract][Full Text] [Related]
15. Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106.
Shimamoto Y; Kazuno H; Murakami Y; Azuma A; Koizumi K; Matsuda A; Sasaki T; Fukushima M
Jpn J Cancer Res; 2002 Apr; 93(4):445-52. PubMed ID: 11985795
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
[TBL] [Abstract][Full Text] [Related]
17. Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
Weinreich J; Schott S; Königsrainer I; Zieker D; Königsrainer A; Schott H
Invest New Drugs; 2011 Dec; 29(6):1294-302. PubMed ID: 20596746
[TBL] [Abstract][Full Text] [Related]
18. Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3'-ethynylcytidine treatment of human cancer cells.
Sato A; Takano T; Hiramoto A; Naito T; Matsuda A; Fukushima M; Wataya Y; Kim HS
Anticancer Drugs; 2017 Aug; 28(7):781-786. PubMed ID: 28542039
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.
Smith DB; Martin JA; Klumpp K; Baker SJ; Blomgren PA; Devos R; Granycome C; Hang J; Hobbs CJ; Jiang WR; Laxton C; Le Pogam S; Leveque V; Ma H; Maile G; Merrett JH; Pichota A; Sarma K; Smith M; Swallow S; Symons J; Vesey D; Najera I; Cammack N
Bioorg Med Chem Lett; 2007 May; 17(9):2570-6. PubMed ID: 17317178
[TBL] [Abstract][Full Text] [Related]
20. An efficient synthesis and biological study of novel indolyl-1,3,4-oxadiazoles as potent anticancer agents.
Kumar D; Sundaree S; Johnson EO; Shah K
Bioorg Med Chem Lett; 2009 Aug; 19(15):4492-4. PubMed ID: 19559607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
